Table 3.
Multivariable competing risk analyses predicting the risk of overall recurrence and cancer specific mortality (CSM) in patients treated with radical cystectomy in overall patients.
| Variables | Overall Recurrence | CSM | ||
|---|---|---|---|---|
| HR (CI 95%) | p Value | HR (CI 95%) | p Value | |
| Gender (male vs. female) | 1.07 (0.97–1.17) | 0.1 | 1.15 (1.04–1.27) | 0.005 |
| Age, years | 1.00 (0.99–1.00) | 0.5 | 1.00 (0.99–1.00) | 0.052 |
| RARC approach | 0.65 (0.34–1.26) | 0.2 | 1.00 (0.45–2.24) | 0.9 |
| pT stage | ||||
| pT0-pT1 | Ref | Ref | Ref | Ref |
| pT2 | 1.35 (1.18–1.55) | <0.001 | 1.49 (1.27–1.73) | <0.001 |
| pT3-4 | 2.10 (1.84–2.40) | <0.001 | 2.62 (2.27–3.03) | <0.001 |
| pN+ | 1.68 (1.51–1.86) | <0.001 | 2.09 (1.88–2.33) | <0.001 |
| Nodes removed | 0.99 (0.99–1.00) | 0.3 | 0.99 (0.99–1.00) | 0.04 |
| High grade vs. low | 2.53 (1.73–3.71) | <0.001 | 2.37 (1.56–3.60) | <0.001 |
| LVI | 1.44 (1.31–1.57) | <0.001 | 1.33 (1.21–1.46) | <0.001 |
| Positive surgical margins | 1.43 (1.25–1.65) | <0.001 | 1.64 (1.42–1.90) | <0.001 |
| Neoadjuvant chemotherapy | 1.69 (1.36–2.10) | <0.001 | 1.45 (1.15–1.85) | 0.002 |
| Adjuvant chemotherapy | 1.18 (1.06–1.31) | 0.001 | 0.89 (0.80–0.99) | 0.03 |
CSM: cancer specific mortality, HR: Hazard ratio, CI: confidence interval, RARC: robotic assisted radical cystectomy, LVI: lymphovascular invasion.